Middle East Pharmaceutical Industries (4016) Fundamentals 2026 — P/E 20.1x, Revenue Analysis | SniperIQ
Middle East Pharmaceutical Industries (4016) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 2.1B, trading at SAR 60.00 on the SAU. This SniperIQ fundamentals page covers Middle East Pharmaceutical Industries's valuation (P/E 20.1x, P/B 5.0x), profitability (net margin 21.2%), revenue (SAR 460M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Middle East Pharmaceutical Industries's market cap?
Middle East Pharmaceutical Industries (4016) has a market capitalization of approximately SAR 2.1B, trading at SAR 60.00 on the SAU. Market cap moves with the live share price.
What is Middle East Pharmaceutical Industries's P/E ratio?
Middle East Pharmaceutical Industries's trailing twelve-month P/E ratio is 20.1x, with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Middle East Pharmaceutical Industries?
Middle East Pharmaceutical Industries runs a net profit margin of 21.2%, a gross margin of 62.3%, and an operating margin of 23.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Middle East Pharmaceutical Industries generate?
Middle East Pharmaceutical Industries reported revenue of SAR 460M for fiscal year 2025, with net income of SAR 97M and earnings per share (EPS) of 2.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Middle East Pharmaceutical Industries pay a dividend?
Middle East Pharmaceutical Industries offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Middle East Pharmaceutical Industries financially healthy?
Middle East Pharmaceutical Industries carries a debt-to-equity ratio of 0.20x and a current ratio of 2.85x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Middle East Pharmaceutical Industries a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Middle East Pharmaceutical Industries (4016) the key facts are: market cap SAR 2.1B, P/E 20.1x, revenue SAR 460M, 52-week range 53.88572-79.08572. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Middle East Pharmaceutical Industries's full fundamentals live
Get Middle East Pharmaceutical Industries's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.